Why FHTX Stock Fell After Lilly Partnership Ended

Why Foghorn Therapeutics (FHTX) Stock Fell After Lilly Partnership Ended

Foghorn Therapeutics (FHTX) shares fell 46% in pre-market trading after the company announced the end of its Lilly cancer partnership and plans to cut 40% of its workforce as it restructures.

Market News

WHY FHTX STOCK FELL

Why Foghorn Therapeutics (FHTX) Stock Fell After Lilly Partnership Ended

Market data · APIs · MCP vantafin.com/blog

Foghorn Therapeutics (FHTX) shares fell 46% in pre-market trading after the company announced the end of its Eli Lilly cancer partnership and plans to cut 40% of its workforce as it restructures around its SMARCA2 inhibitor program.

What happened

Foghorn Therapeutics disclosed on October 1, 2026, that its cancer collaboration with Eli Lilly had been terminated. The company simultaneously announced a strategic restructuring that includes reducing its workforce by approximately 40%, according to reporting by Barron's. Foghorn also provided an update on its FHD-909 SMARCA2 inhibitor program and outlined revised strategic priorities going forward.

Why the stock moved

The termination of the Lilly partnership eliminates a significant source of expected non-dilutive capital and strategic support for Foghorn's oncology pipeline. The company disclosed the partnership conclusion in a press release through GlobeNewsWire on October 1, 2026. The resulting workforce reduction from 112 employees signals management's view that the company must operate with a leaner structure while it advances its remaining programs independently. FHTX had previously filed an 8-K on August 6, 2026, outlining quarterly results, but the Lilly termination represents a material shift in the company's partnership strategy and financial outlook.

The numbers

Pre-market price: $1.92 per share
Previous close: $3.56 per share
Pre-market decline: -46.07%
Pre-market volume: 510,018 shares
Market capitalization: approximately $112.7 million
Cash runway: expected into 2028

(no chart available)

What to watch

Foghorn will now need to fund its FHD-909 SMARCA2 inhibitor program without Lilly's resources. The company indicated it is focusing on prostate cancer with FHD-909 while discontinuing work on earlier-stage candidates. Investors should monitor the company's updated cash burn rate following the workforce reduction and any indication of new partnership discussions to support the remaining pipeline.

Foghorn Therapeutics (FHTX) quote, filings, and news on Vantafin

Common questions

Why is FHTX stock down today?

Foghorn Therapeutics shares fell 46% pre-market after the company announced its Lilly cancer partnership had ended and it would cut 40% of its workforce while shifting strategic priorities.

What happened to the Foghorn Lilly partnership?

The collaboration with Eli Lilly has been terminated, forcing Foghorn to restructure and reduce its workforce from 112 employees as it focuses on its SMARCA2 inhibitor FHD-909 program.

How long can Foghorn Therapeutics operate with its current cash?

The company expects its existing cash and investments to fund operations into 2028, though the reduced workforce and pipeline shift may extend that runway.